Pradaxa oral pellets
通用名称
dabigatran etexilate
儿科标签批准日期
2021/6/21 0:00:00
特定指示/秒
Venous thromboembolic events (VTE) in pediatric patients aged 3 months to 11 years who have been treated with a parenteral anticoagulant for at least 5 days; To reduce the risk of recurrence of VTE in pediatric patients aged 3 months to 11 years who have been previously treated
标签更改摘要
- Safety and effectiveness of Pradaxa oral pellets for the treatment and the reduction in risk of recurrence of venous thromboembolism have been established in pediatric patients less than 12 years. Use for this indication is supported by evidence from adequate and well-controlled studies in pediatric patients.
- Other age-appropriate pediatric formulations of dabigatran etexilate are available for pediatric patients aged 12 years and older for these indications.
- Safety and effectiveness have not been established in pediatric patients with non-valvular atrial fibrillation or those who have undergone hip replacement surgery.
- Information on dosing, adverse reactions, PK parameters, and clinical trials.
- Postmarketing study.
- Postmarketing study.
- New dosage form.
研究年龄
6 MONTHS - 18 YEARS
0 YEARS - 17 YEARS
41 DAYS - 24 WEEKS
1 YEARS - 11 YEARS
13 YEARS - 17 YEARS
学习类型
Safety,Pharmacokinetic,Pharmacodynamic
Efficacy,Safety,Pharmacokinetic,Pharmacodynamic
Safety,Pharmacokinetic,Pharmacodynamic,Tolerability
Safety,Pharmacokinetic,Pharmacodynamic,Tolerability
Safety,Pharmacokinetic,Pharmacodynamic,Tolerability
研究设计
Multicenter,Open-Label,Phase 2,Phase 3,Prospective,Single-arm
Multicenter,Randomized,Active Comparator,Parallel Group,Open-Label,Phase 2,Phase 3,Non-Inferiority
Multicenter,Open-Label,Single-dose,Phase 2,Non-Randomized,Single-arm
Multicenter,Open-Label,Single-dose,Phase 2,Non-Randomized,Single-arm
Multicenter,Open-Label,Phase 2,Non-Randomized,Single-arm
西班牙裔拉美裔/拉丁裔总计
9
11
0
N/A
N/A
非西班牙裔/非拉丁裔总人数
203
255
7
N/A
N/A
美洲印第安人/阿拉斯加本地人总数
0
0
0
0
0
国家
United States,Austria,Belgium,Brazil,Canada,Czech Republic,Denmark,France,Germany,Hungary,Israel,Italy,Lithuania,Mexico,Norway,Russian Federation,Sweden,Switzerland,Taiwan,Thailand,Turkey,Ukraine
United States,Argentina,Austria,Belgium,Brazil,Canada,Czech Republic,Denmark,Finland,France,Germany,Greece,Hungary,Israel,Italy,Lithuania,Mexico,Norway,Russian Federation,Spain,Sweden,Switzerland,Taiwan,Thailand,Turkey,Ukraine
Canada,France,Russian Federation
Canada,Italy,Lithuania,Russian Federation,Switzerland,Thailand
Canada